U.S.-based production house Lonestar Films has signed Indian actors Sharib Hashmi (Amazon Prime Video’s “The Family Man”), and Aahana Kumra, (“Lipstick Under My Burkha” and Netflix’s “Call My Agent Bollywood”) for “Cancer” its foray into Bollywood film production. The high concept Hindi-language thriller will be directed by Faisal Hashmi.
Founded by Texas-based entrepreneur Pankaj Mamtora, Lonestar Films describes its maiden Indian production as a “mind-bending thriller.” Currently in pre-production, “Cancer” is expected to begin production early next year. A third lead actor is yet to join the cast.
“I have not seen anything like this on an Indian screen. I’m highly impressed by Faisal Hashmi who is a man of few words. I cannot wait to start shooting for this amazing, unique story,” said Sharib Hashmi.
Faisal Hashmi’s previous directing work has been in the Gujarati film industry. His credits include 2017 romantic comedy “Vitamin She” and 2019’s Short Circuit.
Founded by Texas-based entrepreneur Pankaj Mamtora, Lonestar Films describes its maiden Indian production as a “mind-bending thriller.” Currently in pre-production, “Cancer” is expected to begin production early next year. A third lead actor is yet to join the cast.
“I have not seen anything like this on an Indian screen. I’m highly impressed by Faisal Hashmi who is a man of few words. I cannot wait to start shooting for this amazing, unique story,” said Sharib Hashmi.
Faisal Hashmi’s previous directing work has been in the Gujarati film industry. His credits include 2017 romantic comedy “Vitamin She” and 2019’s Short Circuit.
- 11/22/2022
- by Udita Jhunjhunwala
- Variety Film + TV
IMDb.com, Inc. takes no responsibility for the content or accuracy of the above news articles, Tweets, or blog posts. This content is published for the entertainment of our users only. The news articles, Tweets, and blog posts do not represent IMDb's opinions nor can we guarantee that the reporting therein is completely factual. Please visit the source responsible for the item in question to report any concerns you may have regarding content or accuracy.